Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: Smoke Reader who wrote (45933)	4/28/2018 11:12:44 AM
From: weatherproof	4 Recommendations Recommended By Fitzhughlaw idahoranch1 ladyPI Renmanco Read Replies (2) \| Respond to of 63283

Thanks, Smokey. I should have looked that up before I started my last post, but I suppose it doesn't fight with my working theory. Friends have asked me if they should buy the stock now. I cannot answer that for anyone, as I do not know their financial situation, their current investment portfolio in terms of how diverse it is, or one's tolerance for risk. Nor am I qualified to answer such questions. What I will say is that the manner in which IMMU and others (e.g. Royal Pharma) are investing in ramping up for commercialization of IMMU-132 before approval, suggests that there is an extreme level of confidence pointing toward accelerated approval being imminent. If you've ever cursed yourself for not buying, or buying in early and then selling prematurely, Apple or Google in the beginning stages of those issues, I suppose this is what those foregone opportunities looked like way back when. Does that mean we're definitely going to the moon, that there is no risk? Of course not! I'm simply suggesting that this is an exciting time in IMMU's life cycle to be in it. We're at the intersection of fortune and folly.